{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:08:31Z","timestamp":1778947711920,"version":"3.51.4"},"reference-count":16,"publisher":"Scientific Scholar","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/0378-6323.136832","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T08:30:09Z","timestamp":1405585809000},"page":"300","source":"Crossref","is-referenced-by-count":21,"title":["Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus"],"prefix":"10.25259","volume":"80","author":[{"given":"PradnyaJ","family":"Londhe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"UdayS","family":"Khopkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Kalyanpad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.136832-1","first-page":"1443","volume-title":"Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody- mediated diseases","author":"Stanley","year":"1989","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0378-6323.136832-2","first-page":"291","volume-title":"Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion","author":"Stanley","year":"1993","journal-title":"Adv Immunol"},{"key":"key-10.4103\/0378-6323.136832-3","first-page":"869","volume-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion","author":"Amagai","year":"1991","journal-title":"Cell"},{"key":"key-10.4103\/0378-6323.136832-4","first-page":"371","volume-title":"Dexamethasone-cyclophosphamide pulse therapy in pemphigus","author":"Kaur","year":"1990","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0378-6323.136832-5","first-page":"439","volume-title":"Pemphigus in India","author":"Kanwar","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.136832-6","first-page":"56","volume-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"key-10.4103\/0378-6323.136832-7","first-page":"529","volume-title":"Relevance of rituximab therapy in pemphigus vulgaris: Analysis of current data and the immunologic basis for its observed responses","author":"Feldman","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"key-10.4103\/0378-6323.136832-8","first-page":"1043","volume-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.136832-9","first-page":"422","volume-title":"Patterns of remission in pemphigus vulgaris","author":"Herbst","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.136832-10","first-page":"17","volume-title":"Rituximab in the treatment of pemphigus vulgaris","author":"Zakka","year":"2012","journal-title":"Dermatol Ther (Heidelb)"},{"key":"key-10.4103\/0378-6323.136832-11","first-page":"545","volume-title":"A single cycle of rituximab for the treatment of severe pemphigus","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.136832-12","first-page":"E10","volume-title":"Infusion reactions: Diagnosis, assessment, and management","author":"Vogel","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"key-10.4103\/0378-6323.136832-13","first-page":"382","volume-title":"Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins","author":"Shimanovich","year":"2008","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.136832-14","first-page":"352","volume-title":"Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.136832-15","first-page":"2691","volume-title":"Neutropenia in patients treated with rituximab","author":"Voog","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.136832-16","first-page":"308","volume-title":"Late-onset neutropenia after rituximab treatment: Case series and comprehensive review of the literature","author":"Wolach","year":"2010","journal-title":"Medicine (Baltimore)"}],"container-title":["Indian Journal of Dermatology, Venereology, and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:39:45Z","timestamp":1612658385000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/intermediate-doses-of-rituximab-used-as-adjuvant-therapy-in-refractory-pemphigus\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"alternative-id":["136832"],"URL":"https:\/\/doi.org\/10.4103\/0378-6323.136832","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}